Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EBIT: 2018-2025

Historic EBIT for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -$65.6 million.

  • Bicycle Therapeutics' EBIT fell 2.67% to -$65.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$290.0 million, marking a year-over-year decrease of 47.63%. This contributed to the annual value of -$209.9 million for FY2024, which is 10.49% down from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' EBIT is -$65.6 million, which was up 24.31% from -$86.6 million recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' EBIT peaked at -$14.3 million during Q3 2021, and registered a low of -$86.6 million during Q2 2025.
  • Over the past 3 years, Bicycle Therapeutics' median EBIT value was -$54.2 million (recorded in 2023), while the average stood at -$56.6 million.
  • In the last 5 years, Bicycle Therapeutics' EBIT grew by 24.13% in 2024 and then slumped by 121.35% in 2025.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' EBIT stood at -$18.0 million in 2021, then plummeted by 78.71% to -$32.2 million in 2022, then slumped by 68.37% to -$54.2 million in 2023, then dropped by 24.76% to -$67.7 million in 2024, then declined by 2.67% to -$65.6 million in 2025.
  • Its last three reported values are -$65.6 million in Q3 2025, -$86.6 million for Q2 2025, and -$70.2 million during Q1 2025.